|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
|
21895872 |
2011 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
O(6)-Methylguanine DNA methyltransferase (MGMT) cancels the anticancer effect of temozolomide (drug for glioblastoma), which introduces methylation to DNA.
|
25173514 |
2015 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
|
29808316 |
2018 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.
|
28643151 |
2017 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The purpose of this study was to determine the effect of disulfiram (DSF), an aldehyde dehydrogenase inhibitor, on in vitro radiosensitivity of glioblastoma cells with different methylation status of O6-methylguanine-DNA methyltransferase (MGMT) promoter and the underlying mechanism of such effect.
|
30121967 |
2019 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Therefore, we evaluated the associations between MGMT promoter methylation and prognosis of patients with glioblastoma (GBM).
|
28266716 |
2018 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
|
19188675 |
2009 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Transfection of these three novel miRNAs into the T98G glioblastoma cell line suppressed MGMT mRNA and protein expression.
|
27057640 |
2016 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Promoter methylation status of the DNA repair enzyme O(6)-methylguanine DNA methyltransferase (MGMT) is the most important clinical biomarker in glioblastoma, predicting for therapeutic response.
|
26940435 |
2016 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Exploring this novel combined approach in the clinic to treat glioblastoma patients with MGMT promoter-unmethylated tumors is warranted.
|
30537486 |
2019 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
|
26976423 |
2016 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.
|
23319055 |
2013 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
INI1 immunohistochemical expression in glioblastoma: correlation with MGMT gene promoter methylation status and patient survival.
|
21240060 |
2011 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Temozolomide (TMZ), as the first-line chemotherapy agent used in patients with glioblastoma, has demonstrated different effects in patients due to the expression of O6-methylguanine-DNA methyltransferase (MGMT) which is able to repair the DNA lesions induced by TMZ.
|
29151909 |
2017 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the frequency of pseudoprogression of glioblastoma in Chinese patients receiving concomitant chemoradiotherapy and investigate its association with pseudoprogression and tumour molecular marker O(6)-methylguanine-DNA methyltransferase promoter methylation status.
|
22665686 |
2012 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis.
|
29483008 |
2018 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.
|
28800313 |
2017 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.
|
27409829 |
2016 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Conclusion ADC histogram analysis had incremental prognostic value over MGMT promoter methylation status in patients with glioblastoma.
|
27120357 |
2016 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association between gene copy number variation, predicted MGMT methylation, and MGMT expression revealed a gene dosage effect on MGMT expression in lower grade glioma (World Health Organization grade II/III) that in contrast to glioblastoma usually carry two copies of chromosome 10 on which MGMT resides (10q26.3).
|
26927331 |
2016 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We correlated HMGA 2 expression with clinical parameters, survival, and O-6-methylguanine-DNA methyltransferase methylation status (MGMT) in glioblastoma patients.
|
26892260 |
2016 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT) is a validated predictor of benefit from temozolomide (TMZ) in glioblastoma.
|
30579113 |
2019 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
|
25105699 |
2014 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
To retrospectively determine whether the apparent diffusion coefficient (ADC) values correlate with O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation semiquantitatively analyzed by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) in patients with glioblastoma.
|
23023975 |
2013 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The proposed prognostic scoring system including clinical variables and MGMT promoter methylation status proved valuable in patients with primary conventional glioblastoma, especially those treated with postoperative chemoradiotherapy.
|
23389363 |
2012 |